WHAT IS CLAIMED IS:

1. A compound with the following structure:



or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein:

L^1, L^2, and L^4 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, -C(O)-, -S-, -SO-, -SO_2-, -O-, -$NHSO_2$-, -NHC(O)-, or –NR^5-;

R^1, R^2, and R^4 are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl;

R^5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl;

V is hydrogen or substituted or unsubstituted alkyl;

W is absent, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(O)R^6, -C(O)OR^6, -

$C(O)NR^6R^7$, $-SR^6$, $-SOR^6$, $-SO_2R^6$, $-SO_2NR^6R^7$, $-OR^6$, $-NHSO_2R^6$, or $-NR^6R^7$, where R^6 and R^7 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R^6 and R^7 can be combined if both are present to form a substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;

X is a bond, substituted or unsubstituted alkylene, -O-, or $-NR^8-$;

Y is a bond, substituted or unsubstituted alkylene, -O-, or –N-, provided that when Y is -O-, W is absent; and

Z is a bond, -C(O)-, substituted or unsubstituted alkylene, -O-, or $-NR^9-$;

wherein R^8 and R^9 are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, $-C(O)R^6$, $-C(O)OR^6$, $-C(O)NR^6R^7$, $-SR^6$, $-SOR^6$, $-SO_2R^6$, $-SO_2NR^6R^7$, $-OR^6$, $-NHSO_2R^6$, or $-NR^6R^7$, wherein R^6 and R^7 are as defined above; and

provided that either at least one of X is -O- or $-NR^8-$, Y is -O- or –N-, or Z is -O- or $-NR^9-$.

2. The compound of claim 1, wherein X is a bond or substituted or unsubstituted alkylene.

3. The compound of claim 2, wherein Z is a bond or substituted or unsubstituted alkylene.

4. The compound of claim 3, wherein Y is –N-, and W is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, $-C(O)R^6$, $-C(O)OR^6$, $-C(O)NR^6R^7$, $-SO_2R^6$, or $SO_2NR^6R^7$, wherein R^6 and R^7 are independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl, or R^6 and

R^7 can be combined if both are present to form a substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

5. The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and Z is a bond.

6. The compound of claim 4, wherein X is a bond, and Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

7. The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and wherein Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

8. The compound of claim 7, wherein X and Z are both branched alkylene and X and Z are covalently attached.

9. The compound of any of claims 6-8, wherein Z is selected from the group consisting of substituted methylene, substituted ethylene, substituted propylene, substituted butylene, and substituted pentylene, having one or more substituent groups selected from the group consisting of -OH, $-NH_2$, -SH, -CN, $-CF_3$, $-NO_2$, oxo, halogen, -COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

10. The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and wherein Z is -C(O)-.

11. The compound of any of claims 4-10, wherein W is hydrogen.

12. The compound of any of claims 4-10, wherein W is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, $-C(O)R^6$, $-C(O)OR^6$, $-C(O)NR^6R^7$, $-SR^6$, $-SOR^6$, $-SO_2R^6$, and $-SO_2NR^6$.

13. The compound of claim 12, wherein W is substituted alkyl, substituted heteroalkyl, substituted alkenyl, substituted heteroalkenyl, substituted cycloalkyl, or substituted heterocycloalkyl, having one or more substituent groups selected from the group consisting of -OH, $-NH_2$, -SH, -CN, $-CF_3$, $-NO_2$, oxo, halogen, -COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

14. The compound of claim 12, wherein W is $-COR^6$, $-C(O)OR^6$, $-C(O)NR^6R^7$, $-SO_2R^6$ or $-SO_2NR^6R^7$, and wherein R^6 and R^7 are selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R^6 and R^7 combine to form a substituted or unsubstituted alkylene.

15. The compound of claim 1, wherein W is absent, X is $–NR^8-$, Y is a bond or substituted or unsubstituted alkylene, and Z is $–NR^9-$.

16. The compound of claim 15, wherein Y is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

17. The compound of claim 16, wherein R^8 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, $-COR^6$, $-C(O)OR^6$, $-C(O)NR^6R^7$, $-SR^6$, $-SOR^6$, $-SO_2R^6$, and $-SO_2NR^6R^7$, and wherein R^9 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or

unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, -COR^6, -$C(O)OR^6$, -$C(O)NR^6R^7$, -SR^6, -SOR^6, -SO_2R^6, and -$SO_2NR^6R^7$.

18. The compound of claim 3, wherein Y is -O-, and W is absent.

19. The compound of claim 18, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and Z is a bond.

20. The compound of claim 18, wherein X is a bond, and Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

21. The compound of claim 18, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and wherein Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

22. The compound of any of claims 1-21, wherein V is hydrogen or substituted or unsubstituted methyl.

23. The compound according to any of claims 1-22, wherein L^1 is -S-, -O-, -NR^5-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene; R^1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; and R^5 is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heterocycloalkyl.

24. The compound according to claim 23, wherein L^1 is -NR^5- or substituted or unsubstituted heteroalkyl, and R^1 is substituted or unsubstituted alkyl or substituted or unsubstituted heteroaryl.

25. The compound according to claim 24, wherein L^1 is -NR^5-, and R^1 is substituted alkyl having one or more substituent groups selected from the group

consisting of substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl.

26. The compound according to claim 25, wherein R^1 is substituted alkyl substituted by chloro-substituted thiophenyl.

27. The compound according to claim 24, wherein L^1 is substituted or unsubstituted heteroalkyl, and R^1 is substituted or unsubstituted heteroaryl.

28. The compound according to any of claims 1-27, wherein L^2 is bond, substituted or unsubstituted alkylene, -C(O)-, or -SO_2-, and R^2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

29. The compound according to claim 28, wherein L^2 is bond, and R^2 is hydrogen.

30. The compound according to claim 28, wherein L^2 is-C(O)-, and R^2 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

31. The compound according to any of claims 1-30, wherein L^4 is a bond, and R^4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

32. The compound according to any of claims 1 to 31 as set forth in Table A, Table B, Table C, or Table D.

33. A pharmaceutical composition comprising a compound according to any of claims 1 to 31, or a compound as set forth in Table A, Table B, Table C, or Table D and a pharmaceutically acceptable excipient.

34. A method for treating and/or preventing a disease or disorder in a subject, comprising administering a compound according to any of claims 1 to 32 or a

pharmaceutical composition according to claim 33, to a subject in need thereof in an amount effective to treat or prevent said disease or disorder.

35. The method according to claim 34, wherein said disease or disorder is a thrombotic disease or disorder and/or involves a blood clot thrombus or the potential formation of a blood clot thrombus.

36. The method according to claim 35, wherein said thrombotic disease or disorder comprises acute coronary syndrome, thromboembolism, and/or thrombosis.

37. The method according to claim 36, wherein the thromboembolism comprises venous thromboembolism, arterial thromboembolism, and/or cardiogenic thromboembolism.

38. The method according to claim 37, wherein the venous thromboembolism comprises deep vein thrombosis and/or pulmonary embolism.

39. The method according to claim 38, wherein the deep vein thrombosis and/or pulmonary embolism occurs following a medical procedure.

40. The method according to claim 35, wherein said thrombotic disease or disorder involves dysfunctional coagulation or disseminated intravascular coagulation.

41. The method according to claim 40, wherein the subject is undergoing percutaneous coronary intervention (PCI).

42. The method according to claim 35, wherein said thrombotic disease or disorder involves a blood clot thrombus or the potential formation of a blood clot thrombus and further involves stroke and/or one or more transient ischemic attacks (TIA).

43. The method according to claim 42, wherein said thrombotic disease or disorder involving a blood clot thrombus or the potential formation of a blood clot thrombus further involves stroke and wherein the subject has non-valvular atrial fibrillation.

44. The method according to claim 35, wherein said thrombotic disease or disorder involves a blood clot thrombus or the potential formation of a blood clot thrombus and further involves pulmonary hypertension.

45. The method according to claim 44, wherein the pulmonary hypertension is caused by one or more left heart disorder and/or chronic thromboembolic disease.

46. The method according to claim 44, wherein the pulmonary hypertension is associated with one or more lung disease, including pulmonary fibrosis (idiopathic or otherwise), and/or hypoxia.

47. The method according to claim 34, wherein said disease or disorder comprises fibrosis, Alzheimer's Disease, multiple sclerosis, pain, cancer, inflammation, and/or Type I diabetes mellitus.

48. The method according to claim 34, wherein the disease or disorder involves recurrent cardiac events after myocardial infarction.

49. The method according to claim 37, wherein the venous thromboembolism is associated with formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus.

50. The method according to claim 49, wherein the one or more risk factors comprise a previous venous thromboembolism.

51. The method according to claim 37, wherein the cardiogenic thromboembolism is due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, and/or embolism of peripheral arteries caused by a detached thrombus.

52. The method according to claim 51, wherein the detached thrombus is in the brain (ischemic stroke).

53. The method according to claim 52, wherein the detached thrombus causes a transient ischemic attack (TIA).

54. The method according to claim 51, wherein the cardiogenic thromboembolism is due to non-valvular atrial fibrillation.

55. The method according to claim 36, wherein the thrombosis is arterial thrombosis.

56. The method according to claim 55, wherein the arterial thrombosis is due to one or more underlying atherosclerotic processes in the arteries.

57. The method according to claim 56, wherein the one or more underlying atherosclerotic processes in the arteries obstruct or occlude an artery, cause myocardial ischemia (angina pectoris, acute coronary syndrome), cause myocardial infarction, obstruct or occlude a peripheral artery (ischemic peripheral artery disease), and/or obstruct or occlude the artery after a procedure on a blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries).

58. The method according to claim 34, wherein the treatment or prevention comprises an adjunct therapy.

59. The method according to claim 58, wherein the subject has myocardial infarction, and the adjunct therapy is in conjunction with thrombolytic therapy.

60. The method according to claim 58, wherein the subject has unstable angina pectoris, thrombosis, and/or heparin-induced thrombocytopenia, and the adjunct therapy is in combination with antiplatelet therapy.

61. The method according to claim 58, wherein the subject has non-valvular atrial fibrillation, and the adjunct therapy is in conjunction with one or more other therapies.

62. The method according to claim 34, wherein said disease or disorder is a kallikrein-related disorder.

63. The method according to claim 62, wherein said kallikrein-related disorder is a thrombotic disease, a fibrinolytic disease, a fibrotic disorder, a type of cancer, an inflammatory condition, or a dermatological condition.

64. The method according to claim 62, wherein said kallikrein-related disorder is an ophthalmic disease.

65. The method according to claim 64, wherein said compound or pharmaceutical composition is administered in the form of an ophthalmic composition applied topically to the eye.

66. The method according to claim 65, wherein the ophthalmic composition is in the form of eye drops.

67. The method according to claim 64, wherein said compound or pharmaceutical composition is administered in the form of an ophthalmic composition via intravitreal injection.

68. The method according to claim 64, wherein said ophthalmic disease is diabetic macular edema, age-related macular degeneration, or diabetic retinopathy.

69. The method according to claim 63, wherein said type of cancer is selected from the group consisting of cervical-, testicular-, or non-small-cell lung adenocarcinoma, limited small cell lung cancer, glioma, malignant breast cancer, micrometastasis (e.g. micrometastasis of blood or liver), lung metastasis, and prostatic cancer.

70. The method according to claim 63, wherein said inflammatory condition is sepsis, inflammatory bowel disease, inflammatory arthritis, systemic inflammatory response syndrome, hereditary angioedema, or rheumatoid arthritis.

71. The method according to claim 63, wherein said dermatological condition is atopic dermatitis, psoriasis, or Netherton Syndrome.

72. The method according to any of claims 34-71, wherein said compound acts by inhibiting thrombin and/or kallikrein.

73. The method according to claim 72, wherein said compound acts by inhibiting tissue kallikrein and/or plasma kallikrein.

74. The method according to claim 34, wherein the amount of compound administered is a therapeutically effective dose sufficient to achieve an initial concentration of the compound or its active metabolite(s) in plasma within a range of 1–10 nM, 10–100 nM, 0.1–1 μM, 1–10 μM, 10–100 μM, 100–200 μM, 200–500 μM, or 500–1000 μM, or greater.

75. The method according to claim 74, wherein greater than 50% of the initial compound concentration persists in the plasma for 1 hour, 3 hours, or longer, after intravenous injection.

76. A compound according to any of claims 1 to 32 or a pharmaceutical composition according to claim 33 for use in a method according to any of claims 34-75.

77. The compound according to any of claims 1-32, wherein the compound has inhibitory activity against thrombin and/or plasma kallikrein within a range of 1–10 nM, 10–100 nM, 0.1–1 μM, 1–10 μM, 10–100 μM, 100–200 μM, 200–500 μM, or 500–1000 μM, or greater.

WHAT IS CLAIMED IS:

1. A compound with the following structure:



or pharmaceutically acceptable salt or ester thereof, wherein:

L^1 is $–NR^5$-;

L^2 is bond or -C(O)-, provided that when L^2 is bond, R^2 is hydrogen;

L^4 is a bond;

R^1 is substituted C_1-C_4 alkyl having one or more substituent groups selected from the group consisting of substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl;

R^2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl;

R^4 is hydrogen, substituted or unsubstituted C_1-C_4 alkyl, or substituted or unsubstituted C_1-C_4 heteroalkyl;

R^5 is hydrogen, or substituted or unsubstituted C_1-C_4 alkyl;

V is hydrogen or substituted or unsubstituted alkyl;

W is absent, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, $-C(O)R^6$, $-C(O)NR^6R^7$, $-SO_2R^6$, or $-SO_2NR^6R^7$, where R^6 and R^7 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, or

substituted or unsubstituted heteroaryl, wherein R^6 and R^7 can be combined if both are present to form a substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;

X is a bond, substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, substituted or unsubstituted pentylene, -O-, or $–NR^8$-;

Y is a bond, substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, substituted or unsubstituted pentylene, -O-, or –N-, provided that when Y is -O-, W is absent; and

Z is a bond, -C(O)-, substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, substituted or unsubstituted pentylene, -O-, or $–NR^9$-;

wherein R^8 and R^9 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, $-C(O)R^6$, $-C(O)NR^6R^7$, $-SO_2R^6$, or $-SO_2NR^6R^7$, wherein R^6 and R^7 are as defined above; and

provided that either at least one of X is $-NR^8$-, Y is –N-, or Z is $-NR^9$-; and

wherein for any substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocycloalkenyl a monocyclic ring has 3-8 ring members, a bicyclic ring has 4-16 ring members, and a tricyclic ring has 5f-24 ring members; and

wherein for any substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, each ring contains between 4-20 atoms.

2. The compound of claim 1, wherein X is selected from the group consisting of a bond, substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

3. The compound of claim 2, wherein Z is selected from the group consisting of a bond, substituted or unsubstituted methylene, or substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

4. The compound of claim 3, wherein Y is –N-, and W is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, -$C(O)R^6$, -$C(O)NR^6R^{7,}$ -SO_2R^6, or $SO_2NR^6R^7$, wherein R^6 and R^7 are independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl, or R^6 and R^7 can be combined if both are present to form a substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

5. The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and Z is a bond.

6. The compound of claim 4, wherein X is a bond, and Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

7. The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and wherein Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

8. The compound of claim 7, wherein X and Z are both branched alkylene and X and Z are covalently attached.

9. The compound of claim 4, wherein Z is selected from the group consisting of substituted methylene, substituted ethylene, substituted propylene, substituted butylene, and substituted pentylene, having one or more substituent groups selected from the group consisting of -OH, -NH_2, -SH, -CN, -CF_3, -NO_2, oxo, halogen, -COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

10. The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and wherein Z is -C(O)-.

11. The compound of claim 4, wherein W is hydrogen.

12. The compound of claim 4, wherein W is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, $-C(O)R^6$, $--C(O)NR^6R^7$, $-SO_2R^6$, and $-SO_2NR^6R^7$.

13. The compound of claim 12, wherein W is substituted alkyl, substituted heteroalkyl, substituted alkenyl, or substituted heteroalkenyl, having one or more substituent groups selected from the group consisting of -OH, $-NH_2$, -SH, -CN, $-CF_3$, $-NO_2$, oxo, halogen, -COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

14. The compound of claim 12, wherein W is $-COR^6$, $-C(O)NR^6R^7$, $-SO_2R^6$ or $-SO_2NR^6R^7$, and wherein R^6 and R^7 are selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R^6 and R^7 combine to form a substituted or unsubstituted alkylene.

15. The compound of claim 1, wherein W is absent, X is $–NR^8-$, Y is a bond or substituted or unsubstituted alkylene, and Z is $–NR^9-$.

16. The compound of claim 15, wherein Y is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

17. The compound of claim 16, wherein R^8 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, $-COR^6$, $-C(O)NR^6R^7$, $-SO_2R^6$,

and $-SO_2NR^6R^7$, and wherein R^9 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, $-COR^6$, $-C(O)NR^6R^7$, $-SO_2R^6$, and $-SO_2NR^6R^7$.

18. The compound of claim 1, wherein V is hydrogen or substituted or unsubstituted methyl.

19. The compound according to claim 1, wherein R^1 is substituted alkyl having one or more substituent groups selected from the group consisting of substituted or unsubstituted thiophenyl and substituted or unsubstituted phenyl.

20. The compound according to claim 19, wherein R^1 is substituted alkyl substituted by chloro-substituted thiophenyl.

21. The compound according to claim 1, wherein R^2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

22. The compound according to claim 21, wherein L^2 is bond, and R^2 is hydrogen.

23. The compound according to claim 22, wherein L^2 is -C(O)-, and R^2 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

24. The compound according to claim 1, wherein L^4 is a bond, and R^4 is hydrogen.

25. The compound according to claim 1 as set forth in Table A, Table B, Table C, or Table D.

26. The compound according to claim 23, wherein R^2 is substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl.

27. The compound according to claim 26, wherein R^2 is substituted or unsubstituted phenyl.

28. The compound according to claim 27, wherein R^2 is substituted phenyl having at least one halogen and one carboxylic acid substituent group.

29. The compound according to claim 28, wherein the halogen is selected from the group consisting of chlorine and fluorine.

30. The compound according to claim 29, wherein the halogen is chlorine.

31. The compound according to claim 29, wherein L^4 is a bond, and R^4 is substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.

32. The compound according to claim 31, wherein R^4 is selected from the group consisting of methyl, cyano, and methoxy.

33. A pharmaceutical composition comprising a compound according to claim 1, or a compound as set forth in Table A, Table B, Table C, or Table D and a pharmaceutically acceptable excipient.

34. Use of a compound according to claim 1 in the manufacture of a medicament for the treatment or prevention of a kallikrein-related disease or disorder in a subject in need thereof, wherein the compound is to be administered to the subject in an amount effective to treat or prevent said disease or disorder, wherein said kallikrein-related disorder is an ophthalmic disease selected from the group consisting of diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

35. The use according to claim 34, wherein said compound is to be administered in the form of an ophthalmic composition applied topically to the eye.

36. The use according to claim 35, wherein the ophthalmic composition is in the form of eye drops.

37. The use according to claim 34, wherein said compound is to be administered in the form of an ophthalmic composition via intravitreal injection.